Latest Pyrazines Stories

CAMBRIDGE, Mass., Aug. 27 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced the publication of results from the 682 patient, randomized, Phase III VISTA(1) trial in this week's edition of the New England Journal of Medicine. The results showed a significant survival benefit and a 30 percent complete remission (CR) rate with VELCADE, melphalan and prednisone (VcMP) compared to 4 percent for melaphalan and prednisone (MP) alone in previously untreated multiple myeloma...

Telik has announced that its small molecule proteasome inhibitor program met a preclinical development milestone by demonstrating anticancer activity in preclinical models of human leukemia. The proteasome is an important cellular structure necessary for the growth and function of cancer cells and inhibition of the proteasome has been shown to promote cell cycle arrest and cancer cell death or apoptosis. Bortezomib, an approved drug for the treatment of multiple myeloma, is based on this...

SAN DIEGO, Aug. 18 /PRNewswire/ -- The next time you consider popping a pill when you have trouble nodding off, it might be worth counting sheep instead. A senior psychiatrist at the Scripps Clinic Sleep Center in San Diego, Calif. has found evidence that taking sleeping pills regularly can increase the risk of skin cancer. Daniel F. Kripke, M.D.'s article, based on a compilation of studies involving sleeping pills and cancer, has just been published in the Journal of Sleep Research. It...

Velcade is likely to receive EMEA approval following a positive opinion issued by the EU Committee for Medicinal Products for Human Use for use in previously untreated multiple myeloma patients. Velcade would see considerable uptake if the drug is approved in the first-line setting, due to its proven activity and favorable safety profile compared to current treatment regimens. Velcade (bortezomib; Takeda/Johnson & Johnson) has received a positive opinion from the EU Committee for Medicinal...

CAMBRIDGE, Mass., July 28 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced the initiation of a Phase I trial series of MLN4924, the Company's first-in-class, small molecule inhibitor of the Millennium-discovered target, the Nedd 8 Activating Enzyme (NAE). MLN4924 advanced to the clinic with the first patient dosed in April 2008. The two Phase I dose escalation studies aim to assess safety, tolerability, pharmacokinetic and pharmacodynamic effects in patients with...

WASHINGTON, July 9 /PRNewswire-USNewswire/ -- In a congressional hearing Secretary of Veterans Affairs James B. Peake, M.D., discussed the safety and importance of the research programs operated by the Department of Veterans Affairs (VA) as well as an absolute commitment to its patients, while expressing regret that even a single veteran would feel improperly treated or misused. "VA has an outstanding research program, and has been innovative in its protection of human research subjects,"...

NEW YORK -- Varenicline, a non-nicotine drug designed specifically for smoking cessation, appears to be safe and effective according to a study in the Archives of Internal Medicine.Varenicline is FDA-approved and marketed by Pfizer as Chantix.It binds to a nicotine receptor that's believed to trigger the rewarding effects felt with smoking. Because varenicline competes more strongly than nicotine to bind to the receptor, yet has less of a rewarding effect, the investigators figured that it...

By Anthony J. Brown, MDNEW YORK -- Treatment with a new drug called varenicline (Chantix) may be more effective than bupropion (Zyban) in helping smokers kick the habit, and it may also promote longer-lasting abstinence, suggest results of three studies in the Journal of the American Medical Association this week.However, according to a related editorial, the drug is no panacea for people wishing to quit smoking. "There are some important gastrointestinal side effects and, in the current...

NEW YORK (Reuters Health) - Cognitive behavioral therapy (CBT), a counseling method that emphasizes the role of thinking and behavior modification, is more effective than zopiclone for the short- and long-term treatment of chronic insomnia in older adults, according to a new report. In fact, the study found that zopiclone was no more effect for insomnia than placebo was (a sugar pill.)Zopiclone, sold under the trade name Imovane, is a central nervous system depressant. To prevent excessive...

By Lisa Richwine WASHINGTON (Reuters) - U.S. health regulators on Thursday approved a smoking cessation pill by Pfizer Inc. that helped about one-fifth of cigarette smokers quit the habit for a year in trials. The prescription drug, Chantix, is one of several medicines the world's largest drug maker is counting on to restore earnings growth. Pfizer has forecast annual Chantix sales of $1.2 billion by 2010, but some analysts are skeptical. Chantix works differently than older...